Skip to main content

Gemcitabine Hydrochloride Injection Shortage

Last Updated: September 11, 2025
Status: Discontinued

To Be Discontinued:

Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-0181-25
Status: To Be Discontinued
Date of update: September 11, 2025
Update type: New
Related Information: Discontinuation of the manufacture of the drug
Therapeutic category: Oncology
Date discontinued: September 11, 2025
Initial posting date: September 11, 2025
Contact info: 844-646-4398

Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-0182-25
Status: To Be Discontinued
Date of update: September 11, 2025
Update type: New
Related Information: Discontinuation of the manufacture of the drug
Therapeutic category: Oncology
Date discontinued: September 11, 2025
Initial posting date: September 11, 2025
Contact info: 844-646-4398

Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (Hospira, Inc., a Pfizer Company)

NDC Code: 0409-0183-25
Status: To Be Discontinued
Date of update: September 11, 2025
Update type: New
Related Information: Discontinuation of the manufacture of the drug
Therapeutic category: Oncology
Date discontinued: September 11, 2025
Initial posting date: September 11, 2025
Contact info: 844-646-4398

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer